These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

396 related items for PubMed ID: 31446513

  • 1. Evaluation of telavancin susceptibility in isolates of Staphylococcus aureus with reduced susceptibility to vancomycin.
    McMullen AR, Lainhart W, Wallace MA, Shupe A, Burnham CD.
    Eur J Clin Microbiol Infect Dis; 2019 Dec; 38(12):2323-2330. PubMed ID: 31446513
    [Abstract] [Full Text] [Related]

  • 2. Vancomycin tolerance in methicillin-resistant Staphylococcus aureus: influence of vancomycin, daptomycin, and telavancin on differential resistance gene expression.
    Rose WE, Fallon M, Moran JJ, Vanderloo JP.
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4422-7. PubMed ID: 22687502
    [Abstract] [Full Text] [Related]

  • 3. In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.
    Mendes RE, Moet GJ, Janechek MJ, Jones RN.
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2704-6. PubMed ID: 20385851
    [Abstract] [Full Text] [Related]

  • 4. VISA-Daptomycin non-susceptible Staphylococcus aureus frequently demonstrate non-susceptibility to Telavancin.
    Saravolatz LD, Pawlak J.
    Diagn Microbiol Infect Dis; 2019 Feb; 93(2):159-161. PubMed ID: 30366652
    [Abstract] [Full Text] [Related]

  • 5. Activity of Telavancin against Staphylococcus aureus Isolates, Including Those with Decreased Susceptibility to Ceftaroline, from Cystic Fibrosis Patients.
    Roch M, Varela MC, Taglialegna A, Rose WE, Rosato AE.
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914961
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.
    Steed ME, Vidaillac C, Rybak MJ.
    Antimicrob Agents Chemother; 2012 Feb; 56(2):955-9. PubMed ID: 22123693
    [Abstract] [Full Text] [Related]

  • 7. Antimicrobial Activity of Dalbavancin against Staphylococcus aureus with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from U.S. Medical Centers.
    Sader HS, Mendes RE, Duncan LR, Pfaller MA, Flamm RK.
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263077
    [Abstract] [Full Text] [Related]

  • 8. Telavancin in vitro activity against a collection of methicillin-resistant Staphylococcus aureus isolates, including resistant subsets, from the United States.
    Mendes RE, Sader HS, Flamm RK, Farrell DJ, Jones RN.
    Antimicrob Agents Chemother; 2015 Mar; 59(3):1811-4. PubMed ID: 25561335
    [Abstract] [Full Text] [Related]

  • 9. Prior vancomycin use is a risk factor for reduced vancomycin susceptibility in methicillin-susceptible but not methicillin-resistant Staphylococcus aureus bacteremia.
    Mascitti KB, Edelstein PH, Fishman NO, Morales KH, Baltus AJ, Lautenbach E.
    Infect Control Hosp Epidemiol; 2012 Feb; 33(2):160-6. PubMed ID: 22227985
    [Abstract] [Full Text] [Related]

  • 10. Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection.
    MacGowan AP, Noel AR, Tomaselli S, Elliott HC, Bowker KE.
    Antimicrob Agents Chemother; 2011 Feb; 55(2):867-73. PubMed ID: 21078943
    [Abstract] [Full Text] [Related]

  • 11. Regional analysis of telavancin and comparator antimicrobial activity against multidrug-resistant Staphylococcus aureus collected in the USA 2014-2016.
    Duncan LR, Smith CJ, Flamm RK, Mendes RE.
    J Glob Antimicrob Resist; 2020 Mar; 20():118-123. PubMed ID: 31325617
    [Abstract] [Full Text] [Related]

  • 12. Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies.
    Kosowska-Shick K, Clark C, Pankuch GA, McGhee P, Dewasse B, Beachel L, Appelbaum PC.
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4217-24. PubMed ID: 19620338
    [Abstract] [Full Text] [Related]

  • 13. Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models.
    Smith JR, Barber KE, Hallesy J, Raut A, Rybak MJ.
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5529-34. PubMed ID: 26124162
    [Abstract] [Full Text] [Related]

  • 14. Comparative efficacy of telavancin and daptomycin in experimental endocarditis due to multi-clonotype MRSA strains.
    Xiong YQ, Abdelhady W, Tang C', Bayer AS.
    J Antimicrob Chemother; 2016 Oct; 71(10):2890-4. PubMed ID: 27353467
    [Abstract] [Full Text] [Related]

  • 15. Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011.
    Sader HS, Flamm RK, Jones RN.
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3178-81. PubMed ID: 23629712
    [Abstract] [Full Text] [Related]

  • 16. Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus.
    Saravolatz LD, Pawlak J, Johnson LB.
    J Antimicrob Chemother; 2007 Aug; 60(2):406-9. PubMed ID: 17586562
    [Abstract] [Full Text] [Related]

  • 17. Antibiotic Resistance in the Treatment of Staphylococcus aureus Keratitis: a 20-Year Review.
    Chang VS, Dhaliwal DK, Raju L, Kowalski RP.
    Cornea; 2015 Jun; 34(6):698-703. PubMed ID: 25811722
    [Abstract] [Full Text] [Related]

  • 18. In vivo development of daptomycin resistance in vancomycin-susceptible methicillin-resistant Staphylococcus aureus severe infections previously treated with glycopeptides.
    Capone A, Cafiso V, Campanile F, Parisi G, Mariani B, Petrosillo N, Stefani S.
    Eur J Clin Microbiol Infect Dis; 2016 Apr; 35(4):625-31. PubMed ID: 26815434
    [Abstract] [Full Text] [Related]

  • 19. Telavancin shows superior activity to vancomycin with multidrug-resistant Staphylococcus aureus in a range of in vitro biofilm models.
    Smith K, Gemmell CG, Lang S.
    Eur J Clin Microbiol Infect Dis; 2013 Oct; 32(10):1327-32. PubMed ID: 23624635
    [Abstract] [Full Text] [Related]

  • 20. Emergence of vancomycin-intermediate and -resistant Staphylococcus aureus among methicillin-resistant S. aureus isolated from clinical specimens in the northwest of Iran.
    Ghahremani M, Jazani NH, Sharifi Y.
    J Glob Antimicrob Resist; 2018 Sep; 14():4-9. PubMed ID: 29454049
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.